HOME >> MEDICINE >> NEWS
Enzyme halts muscle waste in mouse models of most-common childhood muscular dystrophy

The muscle destruction associated with Duchenne muscular dystrophy (DMD), the most common childhood form of muscular dystrophy, is halted in mice when supplemental amounts of a naturally occurring enzyme are added to the skeletal muscle.

These results from researchers at the University of California, San Diego (UCSD) School of Medicine are published in the April 16, 2002 issue of the journal Proceedings of the National Academy of Sciences.

Muscle wasting associated with DMD was inhibited after the UCSD team added an enzyme called CT GalNAc transferase to skeletal muscles in mice bred to develop DMD. Normally, CT GalNAc transferase is expressed in another area of the muscle, the neuromuscular junction, where nerves send impulses to muscle fiber. The UCSD team was able to re-position the enzyme so that it was available in the DMD-vulnerable skeletal muscle, which is the structural tissue that supports body movement.

We hope this enzyme can eventually be used as a therapy for Duchenne muscular dystrophy, said Paul Martin, Ph.D., UCSD assistant professor of neurosciences, a member of the UCSD Glycobiology Training and Research Center, and the studys senior author. It has the potential for managing the disease, much like we manage diabetes with insulin medication or injections.

The disease strikes one in 5,000 children, almost exclusively boys, before they reach the age of 6. DMD frequently leaves its victims wheelchair-bound by age 12 and most DMD children die in their early 20s. The disease is caused by a mutation in a protein called dystrophin, which helps anchor muscle fibers to the connective tissue surrounding them.

Losing dystrophin is like losing the foundation of your house, Martin said. Without that foundation, the house falls apart. Without dystrophin, muscles affected by DMD become damaged and break.

Martin discovered the enzyme as he looked for other proteins that might compensate for the disabled dystr
'"/>

Contact: Sue Pondrom
spondrom@ucsd.edu
619-543-6163
University of California - San Diego
15-Apr-2002


Page: 1 2

Related medicine news :

1. Enzyme linked to mania and schizophrenia impairs higher brain functions
2. Enzyme prevents lung damage in premature infants
3. Enzyme found in blood vessels likely target to treat lung injury
4. Enzyme structure holds key to cocaine, heroin metabolism
5. Enzyme replacement therapy found to effectively treat patients with Fabry disease
6. Enzyme level linked to death after angioplasty
7. Enzyme could provide continual fat burning
8. NIH halts use of COX-2 inhibitor in large cancer prevention trial
9. Success of new treatment halts international blood pressure drug trial
10. Researchers identify brain protein that halts progression of Alzheimers
11. New oral medication halts blindness in AIDS patients

Post Your Comments:
(Date:10/22/2014)... Akeso Biomedical, Inc. , a privately held ... infections, microbial biofilms, and chronic wounds, announced that Dr. ... , Dr. Sinskey is a Professor ... of Technology, or MIT. He has been a member ... holds positions as Co-Director of the Malaysia-MIT Biotechnology Partnership ...
(Date:10/22/2014)... TUESDAY, Oct. 21, 2014 (HealthDay News) -- Two sisters ... and heart damage. Ilina and Medha Krishen use ... for sounds of trouble in breathing patterns or heartbeats. ... School in Michigan, wanted to find a way to ... air pollutants. Using an electronic stethoscope, Ilina recorded one ...
(Date:10/22/2014)... 2014 (HealthDay News) -- Measures taken by Firestone officials ... Liberia may have limited the spread of the disease ... The Firestone Natural Rubber Co. provides health services to ... nearby densely populated communities. Between Aug. 1 and ... cases among those 80,000 people. That incidence rate of ...
(Date:10/20/2014)... 20, 2014 The newly updated Worldwide ... of thousands of facts, figures and forecasts on the ... medical sector forecast categories the Worldwide Medical Market ... and national views on the worldwide medical market to ... report gives you data for 2010-2019, covering each country ...
(Date:10/20/2014)... October 20, 2014 The Advocator ... booth at the American Foundation for Suicide Prevention’s (AFSP) ... AFSP is a not-for-profit organization that hosts hundreds of ... from these events are used to help understand and ... and personal relationships as well. , The Advocator ...
Breaking Medicine News(10 mins):Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 2Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 3
(Date:10/22/2014)... October 22, 2014 Oramed ... a clinical-stage pharmaceutical company focused on the development ... top-line clinical results from its Phase IIa clinical ... capsules, to treat type 1 diabetes. The trial was ... under a U.S. Food and Drug Administration ...
(Date:10/22/2014)... Colo. , Oct. 22, 2014   Surefire ... of infusion systems designed to maximize targeted delivery of ... pleased to announce that oncologist John R. Daniels ... Comprehensive Cancer Center, and surgical oncologist Steven C. ... have joined the Company,s Scientific Advisory Board (SAB).    ...
(Date:10/22/2014)... NEW YORK , Oct. 22, 2014 ... and dermatology therapies. PV-10, its novel investigational drug for ... the potential for systemic side effects. Its oncology focus ... liver. Provectus has completed phase 2 trials of PV-10 ... as a topical treatment for atopic dermatitis and psoriasis. ...
Breaking Medicine Technology:Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 4Surefire Medical's Scientific Advisory Board Expands, Broadens Clinical Trial Expertise 2Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2
Cached News: